Dose-dependent olanzapine-associated leukopenia: three case reports.

Abstract:

:Leukopenia and agranulocytosis are well reported and dangerous haematological side-effects associated with the use of typical and atypical antipsychotics. These potentially life-threatening phenomena have led to treatment discontinuation and the consequent reemergence of psychiatric symptoms. We report three cases of patients who developed leukopenia during olanzapine treatment. In each case, the leukopenia was dose-dependent. Reduction in the dose of olanzapine was followed by normalization of the white blood count which allowed continuation of the medication. These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related. Thus, olanzapine dose reduction may permit treatment continuation where this is clinically indicated. In our cases, haematological side-effects were satisfactorily controlled by dose reduction without allowing the reemergence of psychiatric symptoms. This clinical management may offer an alternative to treatment suspension. A careful monitoring of the white blood count is obviously recommended. Olanzapine may be considered a potential and safer treatment for a this specific group of patients.

authors

Kodesh A,Finkel B,Lerner AG,Kretzmer G,Sigal M

doi

10.1097/00004850-200103000-00007

subject

Has Abstract

pub_date

2001-03-01 00:00:00

pages

117-9

issue

2

eissn

0268-1315

issn

1473-5857

journal_volume

16

pub_type

杂志文章
  • Clinical utility of milnacipran in comparison with other antidepressants.

    abstract::The utility of milnacipran in the treatment of major depression has been the subject of an extensive clinical development programme. Comparative studies with tricyclic antidepressant drugs have demonstrated equivalent efficacy, with improved tolerability, in particular with respect to autonomic effects. In comparison ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200206001-00006

    authors: Bisserbe JC

    更新日期:2002-06-01 00:00:00

  • Adverse effects of antipsychotic drugs.

    abstract::The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the conse...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199501005-00005

    authors: Whitworth AB,Fleischhacker WW

    更新日期:1995-01-01 00:00:00

  • Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.

    abstract::Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patie...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Patris M,Bouchard JM,Bougerol T,Charbonnier JF,Chevalier JF,Clerc G,Cyran C,Van Amerongen P,Lemming O,Høpfner Petersen HE

    更新日期:1996-06-01 00:00:00

  • Which antidepressants have demonstrated superior efficacy? A review of the evidence.

    abstract::A review of published evidence of superior efficacy of a particular antidepressant in major depressive disorder may assist clinicians in making considered treatment choices. To identify such candidates, an international group of experts met to assess published evidence (identified through searches in Medline and Embas...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/YIC.0b013e3282eff7e0

    authors: Montgomery SA,Baldwin DS,Blier P,Fineberg NA,Kasper S,Lader M,Lam RW,Lépine JP,Möller HJ,Nutt DJ,Rouillon F,Schatzberg AF,Thase ME

    更新日期:2007-11-01 00:00:00

  • Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis.

    abstract::The present study aimed to systematically compare overall loss to follow-up, discontinuation rates because of adverse events and discontinuation rates because of a lack of efficacy in published studies assessing the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) compared to other second-g...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/00004850-200503000-00001

    authors: Gartlehner G,Hansen RA,Carey TS,Lohr KN,Gaynes BN,Randolph LC

    更新日期:2005-03-01 00:00:00

  • Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.

    abstract::The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200111000-00002

    authors: Zhang XY,Zhou DF,Cao LY,Zhang PY,Wu GY,Shen YC

    更新日期:2001-11-01 00:00:00

  • An open-label study of escitalopram in body dysmorphic disorder.

    abstract::Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000194378.65460.ef

    authors: Phillips KA

    更新日期:2006-05-01 00:00:00

  • Refining treatment approaches in obsessive-compulsive disorder.

    abstract::Obsessive-compulsive disorder (OCD) has emerged as a common but frequently hidden psychiatric disorder which inflicts an intolerable burden on sufferers and demands effective management. For many years, however, OCD was considered treatment resistant and it is only in the past 15 years that effective therapy has becom...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199612005-00003

    authors: Fineberg N

    更新日期:1996-12-01 00:00:00

  • Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study.

    abstract::This study evaluated the efficacy of pregabalin augmentation of antidepressant treatment in patients with posttraumatic stress disorder (PTSD). Nine patients meeting Diagnostic and Statistical Manual, fourth edition criteria for PTSD who were on stable doses of antidepressants were treated open label with flexibly dos...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e32831feea9

    authors: Pae CU,Marks DM,Han C,Masand PS,Patkar AA

    更新日期:2009-01-01 00:00:00

  • Antidepressant interactions with warfarin.

    abstract::The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199803000-00006

    authors: Duncan D,Sayal K,McConnell H,Taylor D

    更新日期:1998-03-01 00:00:00

  • Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria.

    abstract::Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Eriksson E

    更新日期:1999-05-01 00:00:00

  • Construction and validation of the My Medicines and Me Questionnaire for assessment of the self-reported side effects of psychotropic medication.

    abstract::We aimed to construct and assess the psychometric properties of the My Medicines and Me Questionnaire (M3Q), a self-report side-effect questionnaire for mental health patients. Thirty individuals taking a psychotropic medication completed the M3Q side-effect checklist along with the Liverpool University Neuroleptic Si...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000072

    authors: Ashoorian DM,Davidson RM,Rock DJ,Dragovic M,Clifford RM

    更新日期:2015-07-01 00:00:00

  • Prediction of response to acute neuroleptic treatment in schizophrenia.

    abstract::Predicting the outcome of treatment with neuroleptics and understanding the factors that contribute to variability in the response to these drugs have preoccupied researchers and clinicians since the class was developed. Clinicians need empirically based prospective criteria in order to choose a treatment strategy tha...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199605002-00008

    authors: Gaebel W

    更新日期:1996-05-01 00:00:00

  • Novel antipsychotics and negative symptoms.

    abstract::Negative symptoms are a key feature of schizophrenia. Novel (atypical) antipsychotic drugs, unlike conventional antipsychotics, cause substantial reductions in Positive and Negative Symptom Scale (PANSS) scores. Negative symptoms, however, can arise from both the pathology of the disease (primary negative symptoms) an...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199803003-00008

    authors: Möller HJ

    更新日期:1998-03-01 00:00:00

  • Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder.

    abstract::This study aimed to compare the effectiveness of parental training (PT), methylphenidate treatment (MPH), and the combination of PT and MPH treatment (PT/MPH) on school achievements in children with attention-deficit hyperactivity disorder (ADHD). Twenty eight ADHD patients (age: 10.1±1.11 years) were divided into thr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000218

    authors: Golubchik P,Hamerman H,Manor I,Peskin M,Weizman A

    更新日期:2018-07-01 00:00:00

  • Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.

    abstract::Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no sign...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199911000-00003

    authors: Berk M,Ichim L,Brook S

    更新日期:1999-11-01 00:00:00

  • A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment.

    abstract::Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000198

    authors: Drago A,Kure Fischer E

    更新日期:2018-01-01 00:00:00

  • Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.

    abstract::Sertindole is a novel atypical antipsychotic, which has shown efficacy in the treatment of positive and negative symptoms of schizophrenia in phase II and III studies. Furthermore, these studies have demonstrated tolerability and a favourable side-effect profile. In contrast to classical antipsychotics, sertindole was...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200015040-00003

    authors: Pezawas L,Quiner S,Moertl D,Tauscher J,Barnas C,Küfferle B,Wolf R,Kasper S

    更新日期:2000-07-01 00:00:00

  • Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.

    abstract::Recently proposed criteria for remission by a 'Remission in Schizophrenia Working Group' have generated considerable interest. We assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. This allowed us to examine...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/YIC.0b013e32830c2042

    authors: Emsley R,Oosthuizen P,Koen L,Niehaus DJ,Medori R,Rabinowitz J

    更新日期:2008-11-01 00:00:00

  • Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin.

    abstract::It has been suggested that dopamine/serotonin (5-HT) imbalance, with relative enhancement of serotonergic activity, might be one of the possible pathophysiological mechanisms underlying neuroleptic-induced akathisia. On the basis of preclinical data, which imply that the partial 5-HT1A agonist buspirone possesses anti...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-199709000-00003

    authors: Poyurovsky M,Weizman A

    更新日期:1997-09-01 00:00:00

  • Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis.

    abstract::The effect of the antipsychotic drug trifluoperazine (TFP) on the in-vitro growth of 50 clinical isolates of Mycobacterium tuberculosis was tested. Of these isolates, 29 were susceptible to all five of the antitubercular drugs isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide, and 21 were resistant to o...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199805000-00006

    authors: Gadre DV,Talwar V,Gupta HC,Murthy PS

    更新日期:1998-05-01 00:00:00

  • Resurrecting the discussion on neurotoxicity of lithium at therapeutic levels.

    abstract::Lithium is widely used in the treatment of bipolar disorder. Here we describe the syndrome of irreversible lithium-effectuated neurotoxicity in a patient within therapeutic doses and levels, which persisted after discontinuation of Lithium. A 50-year-old gentleman with Bipolar disorder presented with symptoms of Mania...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000341

    authors: Jha A,Pai NM,Ganjekar S,Desai G,Chaturvedi SK

    更新日期:2021-03-01 00:00:00

  • An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.

    abstract::The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/YIC.0000000000000121

    authors: Carrasco JL,Kornstein SG,McIntyre RS,Fayyad R,Prieto R,Salas M,Mackell J,Boucher M

    更新日期:2016-05-01 00:00:00

  • Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia.

    abstract::The pattern of brain metabolic changes produced by olanzapine has yet to be described, despite the theoretical and clinical interest of this new antipsychotic. We studied a group of 17 schizophrenic patients who underwent two fluoro-deoxyglucose-positron emission tomography (FDG-PET) studies under two different condit...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200501000-00003

    authors: Molina V,Gispert JD,Reig S,Pascau J,Martínez R,Sanz J,Palomo T,Desco M

    更新日期:2005-01-01 00:00:00

  • Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.

    abstract::To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depression with comorbid anxiety disorders. Outpatients fulfilling DSM-III-R criteria for major depression or dysthymia and for a co-occurring comorbid anxiety disorder (panic disorder, generalized anxiety disorder or obsess...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200301000-00003

    authors: Pini S,Amador XF,Dell'Osso L,Baldini Rossi N,Cassano P,Savino M,Cassano GB

    更新日期:2003-01-01 00:00:00

  • Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression.

    abstract::Sparse data exist regarding the risks and benefits of treating bipolar-II depression with antidepressants alone. On the basis of studies of bipolar-I patients, treatment guidelines suggest antidepressants should be augmented with mood stabilizers. Whether these recommendations apply to bipolar-II is unclear. A post-ho...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3280c28410

    authors: Agosti V,Stewart JW

    更新日期:2007-09-01 00:00:00

  • Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial.

    abstract::Clozapine is the only evidence-based antipsychotic for treatment-resistant schizophrenia. However, it has considerable side effects, limiting its usability and reducing patients' adherence. One of the most common and distressing side effects is hypersalivation, which can be debilitating, stigmatizing and potentially d...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000251

    authors: Segev A,Evans A,Hodsoll J,Whiskey E,Sheriff RS,Shergill S,MacCabe JH

    更新日期:2019-03-01 00:00:00

  • Patient-based and clinician-based support for the remission criteria in schizophrenia.

    abstract::This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000224791.06159.88

    authors: Docherty JP,Bossie CA,Lachaux B,Bouhours P,Zhu Y,Lasser R,Gharabawi GM

    更新日期:2007-01-01 00:00:00

  • Anticholinergic equivalents and parkinsonism: a model for predicting side-effects of antipsychotic drugs.

    abstract::The tendency of antipsychotics to produce extrapyramidal side-effects varies inversely with their antimuscarinic activity. This paper reviews the antipsychotic and antimuscarinic potency of these drugs and compares the total antimuscarinic activity in standard daily doses of antipsychotics, antiparkinson agents and an...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198701000-00005

    authors: Menkes DB,Clarkson HO,Caradoc-Davies G,Mullen PE

    更新日期:1987-01-01 00:00:00

  • ADDH and methylphenidate responders: effects on behavior controlled by complex reinforcement schedules.

    abstract::One of the most effective treatments for children with Attention Deficit Disorder with Hyperactivity (ADDH) has been the prescription of methylphenidate (MPH). While laboratory-based evidence indicates that MPH effects may be rate-dependent, little is known about changes evinced in operant behavior controlled by compl...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198810000-00006

    authors: DuPaul GJ,Rapport MD,Vyse SA

    更新日期:1988-10-01 00:00:00